In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mylan at last acquires Meda, paying $9.9bn

Executive Summary

Almost two years after launching two separate (but unsuccessful) hostile bids, Mylan NV is taking over publicly traded Swedish spec pharma Meda AB for SEK83.6bn ($9.9bn). Mylan will pay $8.5bn in cash (SEK165 ($19.68) per share, an 84% premium) and debt, and issue about $1.4bn in Mylan stock). The deal is subject to 90% of Meda shareholders tendering their shares; stakeholders accounting for about 30% of shares have already accepted the offer.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies